Advancing Early Alzheimer Diagnosis: Best Practices for Timely Screening and Detection

Panelists discuss how health care institutions employ comprehensive screening protocols for Alzheimer disease, including cognitive assessments, biomarker testing, and regular monitoring of at-risk populations, to facilitate early symptom identification and timely diagnosis that enables prompt intervention and improved patient outcomes.

EP: 1.Strategies for Enhancing Early Diagnosis and Implementation of Disease-Modifying Therapies in Alzheimer Disease

Now Viewing

EP: 2.Advancing Early Alzheimer Diagnosis: Best Practices for Timely Screening and Detection

EP: 3.Care Pathways for Nonspecialist Providers When Evaluating Patients With Potential Mild Cognitive Impairment

EP: 4.Empowering Nonspecialist Providers and Addressing Gaps in Dementia Care: How Tools and Biomarkers Can Help

EP: 5.Factors to Evaluate When Selecting a Combination of Screening Assessments and Tests for Detecting Alzheimer Disease

EP: 6.From Time Constraints to Reimbursement: Addressing Key Hurdles in Cognitive Screening for Alzheimer Disease

EP: 7.Expanding Access to Alzheimer Disease Care: Leveraging Referral Networks and Telemedicine for Patients in Underserved Areas

EP: 8.Amyloid-Targeting Therapies in Alzheimer Disease: Mechanisms of Action, Efficacy, and Safety Considerations

EP: 9.Real-World Implications of Changes in CDR-SB Score in Patients Receiving Amyloid-Targeting Therapy

EP: 10.Patient Selection for Amyloid-Targeting Therapies: Key Characteristics and Considerations

EP: 11.Understanding the Hesitancy to Prescribe Amyloid-Targeting Therapies for Patients With Alzheimer Disease

EP: 12.Navigating the Risk-Benefit Conversation: Discussing Amyloid-Targeting Therapies With Patients and Caregivers

EP: 13.Criteria for Discontinuing Treatment With an Amyloid-Targeting Therapy

EP: 14.Strategies for Clinicians When Developing Protocols for Managing ARIA

EP: 15.Key Barriers in Managing Patients With Mild Cognitive Impairment Using Amyloid-Targeting Therapies

EP: 16.Access to Diagnostic Tests and Coverage for Amyloid-Targeting Therapies: Payer Considerations

EP: 17.Addressing Concerns About the Financial Impact of Amyloid-Targeting Therapies

EP: 18.Final Thoughts Alzheimer Disease Care

Video content above is prompted by the following:

• What are the current best practices your institution uses to screen for Alzheimer disease to ensure timely identification of symptoms and early diagnosis?

Related Videos

Related Content

Advertisement

July 10th 2025

SGLT2 Inhibitor Offers Kidney Protection and Reduces Heart Failure Risk After Acute Myocardial Infarction

Giuliana Grossi

Secondary analysis findings from the EMPACT-MI trial highlight empagliflozin's significant cardiovascular and kidney benefits when initiated soon after an acute myocardial infarction.

December 23rd 2024

Five Years Later: Ongoing COVID-19 Challenges, Next Steps

Brooke McCormick

On this episode of Managed Care Cast, we speak with Jenny Han, MD, of Emory School of Medicine and Grady Hospital, about COVID-19, long COVID, and strategies for prevention and care.

July 8th 2025

Severe COVID-19 Linked to Higher Exacerbation, Mortality Risks in Patients With Bronchiectasis

Brooke McCormick

Patients with bronchiectasis face heightened risks of severe exacerbation and mortality after COVID-19 recovery, especially following severe cases.

December 17th 2024

Diving Into Patient Preferences for Blood Cancer Treatments With Dr Sikander Ailawadhi

Three abstracts presented at the 2024 American Society of Hematology annual meeting focused on patient preferences and treatment choices in blood cancers.

July 8th 2025

Corticosteroid Premedication for Infliximab Remains Unnecessarily Common

Shirley Cohen-Mekelburg, MD, MS Jeffrey Gibbs, MD Beth Wallace, MD, MS Brooke Kenney, MPH Akbar K. Waljee, MD, MSc

Although use of corticosteroid premedication prior to infliximab infusions is declining, it remains unnecessarily high despite limited benefit and the risk of serious adverse events from corticosteroids.

July 8th 2025

Rezpegaldesleukin Potentially Promising for Atopic Dermatitis

Marie Bosslett

Following 16 weeks of rezpegaldesleukin treatment in the REZOLVE-AD study, primary and key secondary end points have been met.

Related Content

Advertisement

July 10th 2025

SGLT2 Inhibitor Offers Kidney Protection and Reduces Heart Failure Risk After Acute Myocardial Infarction

Giuliana Grossi

Secondary analysis findings from the EMPACT-MI trial highlight empagliflozin's significant cardiovascular and kidney benefits when initiated soon after an acute myocardial infarction.

December 23rd 2024

Five Years Later: Ongoing COVID-19 Challenges, Next Steps

Brooke McCormick

On this episode of Managed Care Cast, we speak with Jenny Han, MD, of Emory School of Medicine and Grady Hospital, about COVID-19, long COVID, and strategies for prevention and care.

July 8th 2025

Severe COVID-19 Linked to Higher Exacerbation, Mortality Risks in Patients With Bronchiectasis

Brooke McCormick

Patients with bronchiectasis face heightened risks of severe exacerbation and mortality after COVID-19 recovery, especially following severe cases.

December 17th 2024

Diving Into Patient Preferences for Blood Cancer Treatments With Dr Sikander Ailawadhi

Three abstracts presented at the 2024 American Society of Hematology annual meeting focused on patient preferences and treatment choices in blood cancers.

July 8th 2025

Corticosteroid Premedication for Infliximab Remains Unnecessarily Common

Shirley Cohen-Mekelburg, MD, MS Jeffrey Gibbs, MD Beth Wallace, MD, MS Brooke Kenney, MPH Akbar K. Waljee, MD, MSc

Although use of corticosteroid premedication prior to infliximab infusions is declining, it remains unnecessarily high despite limited benefit and the risk of serious adverse events from corticosteroids.

July 8th 2025

Rezpegaldesleukin Potentially Promising for Atopic Dermatitis

Marie Bosslett

Following 16 weeks of rezpegaldesleukin treatment in the REZOLVE-AD study, primary and key secondary end points have been met.